Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid

The pharma hopes showing a PFS benefit in first-line NSCLC patients with a high tumor mutation burden may provide a way to compete with Merck in that setting, but analysts think it will need overall survival data.